{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:10:15Z","timestamp":1767625815265,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ProA Capital","award":["P2022\/BMD-7321"],"award-info":[{"award-number":["P2022\/BMD-7321"]}]},{"name":"Halekulani S.L.","award":["P2022\/BMD-7321"],"award-info":[{"award-number":["P2022\/BMD-7321"]}]},{"name":"MJR","award":["P2022\/BMD-7321"],"award-info":[{"award-number":["P2022\/BMD-7321"]}]},{"name":"European Development Regional Fund \u201cA way to achieve Europe\u201d","award":["P2022\/BMD-7321"],"award-info":[{"award-number":["P2022\/BMD-7321"]}]},{"name":"Comunidad de Madrid","award":["P2022\/BMD-7321"],"award-info":[{"award-number":["P2022\/BMD-7321"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have benefits for survival in some cancers with peritoneal metastasis. Hematologic toxicity described rate is 2 to 38%. Methods: Patients admitted to an intensive care unit (ICU) after CRS and HIPEC over 78 months. The data recorded were demographic characteristics, the severity of illness, complete blood samples, the type of cancer and extension, HIPEC drug and temperature, ICU and hospital stay and mortality, bleeding, and the need for transfusion of blood products. Results: Of the 96 patients included, 77.1% presented hematological complications: 8.3% leukopenia (&lt;4000\/mm3 leucocytes), 66.7% anemia (hemoglobin &lt; 10 mg\/dL), and 22.9% coagulopathy (INR &lt; 1.5, or\/and aPTT &lt; 45 s, or\/and platelet count &lt; 100,000\/mm3, or\/and &lt;100 mg\/dL of serum fibrinogen). Leukopenia was higher in ovarian cancer or those treated with doxorubicin. Females with anemia, ovarian cancer, and those treated with cisplatin or doxorubicin had longer ICU stays. Bleeding complications were low-corrected in a conservative manner. The median ICU stay was 5 (4.0\u20135.0) days. The ICU mortality rate was 1.0%. Conclusions: In our study, 77.1% of patients treated with CRS and HIPEC developed hematological complications during the postoperative period; the majority of them were not severe and resolved spontaneously, without an effect on mortality or hospital stay.<\/jats:p>","DOI":"10.3390\/jcm12134323","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:45:11Z","timestamp":1687913111000},"page":"4323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hematological Alterations after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2006-9545","authenticated-orcid":false,"given":"Maria","family":"Pintado","sequence":"first","affiliation":[{"name":"Intensive Care Unit, Hospital Universitario Pr\u00edncipe de Asturias, 28805 Alcal\u00e1 de Henares, Spain"},{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Alcal\u00e1 de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Lasa Unz\u00fae","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, General and Digestive Surgery, Hospital Universitario Pr\u00edncipe de Asturias, 28805 Alcal\u00e1 de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remedios","family":"G\u00f3mez Sanz","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, General and Digestive Surgery, Hospital Universitario Pr\u00edncipe de Asturias, 28805 Alcal\u00e1 de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Diez Alonso","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, General and Digestive Surgery, Hospital Universitario Pr\u00edncipe de Asturias, 28805 Alcal\u00e1 de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1708","authenticated-orcid":false,"given":"Miguel","family":"Ortega","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Alcal\u00e1 de Henares, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melchor","family":"\u00c1lvarez de Mon","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Alcal\u00e1 de Henares, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"},{"name":"Inmune System Diseases-Rheumatology and Internal Medicine Service, Hospital Universitario Pr\u00edncipe de Asturias (CIBEREHD), 28806 Alcal\u00e1 de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Nevado Losada","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Hospital Universitario Pr\u00edncipe de Asturias, 28805 Alcal\u00e1 de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Gutierrez Calvo","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, General and Digestive Surgery, Hospital Universitario Pr\u00edncipe de Asturias, 28805 Alcal\u00e1 de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U","article-title":"Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis","volume":"14","author":"Sugarbaker","year":"1998","journal-title":"Semin. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-7819-7-5","article-title":"Peritoneal carcinomatosis: Patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"7","author":"Glockzin","year":"2009","journal-title":"World J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.critrevonc.2019.06.014","article-title":"Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer","volume":"142","author":"Wisselink","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.21614\/chirurgia.114.2.222","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: Our Initial Experience","volume":"114","author":"Bartos","year":"2019","journal-title":"Chirurgia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamasurg.2013.3640","article-title":"Surgical outcomes of hyperthermic intraperitoneal chemotherapy: Analysis of the American college of surgeons national surgical quality improvement program","volume":"149","author":"Jafari","year":"2014","journal-title":"JAMA Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","article-title":"A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"14","author":"Yan","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12630-017-0952-7","article-title":"Coagulation after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective cohort analysis","volume":"64","author":"Hurdle","year":"2017","journal-title":"Can. J. Anaesth."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.23736\/S0026-4733.18.07649-6","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Morbidity and postoperative outcomes","volume":"74","author":"Robella","year":"2019","journal-title":"Minerva Chir."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: A severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: Results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit. Care Med."},{"key":"ref_11","first-page":"496","article-title":"Alterations in hemostasis during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis","volume":"93","author":"Bernard","year":"2015","journal-title":"Cir. Esp."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2044.2007.05380.x","article-title":"Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"63","author":"Schmidt","year":"2008","journal-title":"Anaesthesia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1477-7819-9-169","article-title":"Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC)","volume":"9","author":"Cooksley","year":"2011","journal-title":"World J. Surg. Oncol."},{"key":"ref_14","first-page":"262","article-title":"Hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: A single institution Indian experience","volume":"29","author":"Somashekhar","year":"2016","journal-title":"Natl. Med. J. India"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1245\/s10434-014-4026-6","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: Analysis of 30-day morbidity and mortality","volume":"22","author":"Cripe","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1245\/s10434-018-6630-3","article-title":"Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC","volume":"25","author":"Nizri","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/joacp.JOACP_93_18","article-title":"Anesthetic implications in hyperthermic intraperitoneal chemotherapy","volume":"35","author":"Gupta","year":"2019","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Van Poucke, S., Huskens, D., Van der Speeten, K., Roest, M., Lauwereins, B., Zheng, M.-H., Dehaene, S., Penders, J., Marcus, A., and Lanc\u00e9, M. (2018). Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy\u2014A prospective cohort study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193657"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1245\/s10434-012-2853-x","article-title":"Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Canda","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijsu.2015.02.025","article-title":"Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy","volume":"16","author":"Piccioni","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1245\/s10434-013-3221-1","article-title":"Safety of epidural analgesia in the perioperative care of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"21","author":"Soliz","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/pp-2019-0025","article-title":"Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin","volume":"4","author":"Hakeam","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/pp-2017-0008","article-title":"Neutropenia and thrombocytopenia after cytoreductive surgery and heated intraperitoneal chemotherapy","volume":"2","author":"Finlay","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_24","first-page":"e38","article-title":"Hematological toxicities associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"16","author":"Wong","year":"2019","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.amjsurg.2019.01.034","article-title":"Epidural analgesia? A prospective analysis of perioperative coagulation in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"217","author":"Teoh","year":"2019","journal-title":"Am. J. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0310057X18811993","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy\u2014Perioperative management at Waikato Hospital","volume":"47","author":"Davis","year":"2019","journal-title":"Anaesth. Intensive Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00423-014-1253-z","article-title":"Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"400","author":"Desantis","year":"2015","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1477-7819-12-136","article-title":"Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Retrospective analysis of a single centre three-year experience","volume":"12","author":"Kajdi","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1245\/s10434-012-2496-y","article-title":"Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: A multi-institutional experience","volume":"19","author":"Bell","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4292\/wjgpt.v7.i3.434","article-title":"Incidence of leukopenia after intraperitoneal vs combined intravenous\/intraperitoneal chemotherapy in pseudomyxoma peritonei","volume":"7","author":"Horvath","year":"2016","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1245\/s10434-017-6112-z","article-title":"Conflicting Data on the Incidence of Leukopenia Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin, C","volume":"24","author":"Feferman","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1245\/s10434-009-0523-4","article-title":"Incidence risk, factors, impact of severe neutropenia after hyperthermic intraperitoneal mitomycin, C","volume":"16","author":"Lambert","year":"2009","journal-title":"Ann. Surg. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:02:13Z","timestamp":1760126533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":32,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jcm12134323"],"URL":"https:\/\/doi.org\/10.3390\/jcm12134323","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}